Hummingbird Bioscience and Dartmouth’s Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024 (11:00 AM – 3:30 PM ET).
VISTA is a novel immune checkpoint implicated in various cancers. There is broad potential clinical impact for cancer patients, with strong scientific evidence that VISTA-mediated immune suppression plays a key role in many solid tumors, including triple-negative breast cancer, non-small cell lung cancer and head and neck squamous cell carcinoma. High VISTA expression in tumor correlates with poor survival in cancer patients and has been associated with a lack of response to other immune checkpoint inhibitors. Pre-clinical data on VISTA biology and VISTA targeting have shown potent anti-tumor effects, and clinical readouts are expected this year.
The symposium will explore the important role of VISTA in cancer immunotherapy. Along with updates on the ongoing clinical development of anti-VISTA therapies, renowned scientific experts, clinicians, and industry leaders will share the latest insights on VISTA biology, and the growing potential of VISTA as a therapeutic target in multiple cancer indications. Register here.
